No recommendation
No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.
(Sharecast News) - ValiRx, a life science company focussed on cancer therapeutic development, reported a total comprehensive loss of £0.97m for the six months ended 30 June on Friday, narrowing from a loss of £1.04m in the same period last year.
The AIM-traded company said its loss before income tax also narrowed, to £1.05m from £1.15m a year earlier.
Research and development costs, excluding employee expenses, fell to £0.12m from £0.21m, while administrative expenses remained relatively stable at £0.95m.
Cash and cash equivalents at the end of June stood at £0.81m.
Operationally, ValiRx reported significant milestones, having signed its first US customer for its Inaphaea tCRO service in a multistage deal, and expanded the Inaphaea Biobank to include 2D and 3D patient-derived cell models.
Collaboration agreements were established with DefiniGen and Dundee University, the latter of which launched a pro-senescence project.
ValiRx also started a second evaluation project with Imperial College focused on drug-resistant ovarian cancer, and continued its evaluation of Cytolytix in prostate cancer with the Open University.
At 1027 BST, shares in ValiRx were down 16.76% at 1.42p.
Reporting by Josh White for Sharecast.com.
The value of investments can go down in value as well as up, so you could get back less than you invest. It is therefore important that you understand the risks and commitments. This website is not personal advice based on your circumstances. So you can make informed decisions for yourself we aim to provide you with the best information, best service and best prices. If you are unsure about the suitability of an investment please contact us for advice.
